FDA Approves Shionogi's Xocova as First Oral COVID-19 Post-Exposure Prophylaxis

The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis for COVID-19 in adults and adolescents 12 years of age and older, the company announced on June 1, 2026. The approval, covering use after contact with an individual who has COVID-19, came ahead of the June 16 PDUFA action date, per the company's press release.

What exactly was approved?

Xocova is an oral antiviral approved for post-exposure prophylaxis of COVID-19 following contact with an infected individual, in people 12 and older, per Shionogi's announcement. The regimen is a five-day oral course: three tablets taken on day one and one tablet taken on days two through five, per the same release. The company describes the approval as introducing the first and only oral option to help prevent COVID-19 after exposure in the current therapeutic landscape.

The scope matters. Prophylaxis after a known exposure is a distinct indication from treatment of active infection, and the approval language is framed around prevention during the window between exposure and potential symptom onset. How the product is positioned against vaccination and existing antiviral treatment options is a question for prescribers and payers that the approval release itself does not address; US availability timing and pricing were not yet disclosed as of the announcement.

What did the pivotal trial show?

The approval is based on the SCORPIO-PEP Phase 3 trial, in which ensitrelvir reduced the risk of symptomatic COVID-19 by 67% versus placebo through day 10 after exposure, per the company's press release describing the study. The figure is company-reported from the pivotal program; the full efficacy and safety tables sit in the approved labeling rather than the announcement.

Ensitrelvir was already approved in Japan, and the FDA had accepted the US new drug application with a June 2026 goal date after granting fast track designation for the prophylaxis indication earlier in the program. An approval that lands two weeks ahead of its action date is routine agency timing rather than a signal about review priority, but it does compress launch preparation for what is a prevention product aimed at exposure events rather than diagnosed illness.

Who can use it, and what is not yet known?

The indicated population is people 12 and older who have had contact with someone with COVID-19. What the announcement does not cover is the commercial layer: list price, payer coverage and US launch timing were not stated in the release. Shionogi has said the approval addresses a gap in prevention options, a company framing that independent outcomes data in real-world use will test.

For the biotech industry calendar, the decision adds an oral antiviral brand to the small group of COVID products with active US approvals, and it marks a US regulatory landing for Shionogi's infectious disease franchise. Readers can follow the primary disclosures in the company's June 1 announcement and in the distributed press release text.